Literature DB >> 6203578

CA125 seric levels in non malignant pathologies.

A Ruibal, G Encabo, E Martinéz-Miralles, C Murcia, J A Capdevila, A Salgado, J M Martinéz-Vasquéz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6203578

Source DB:  PubMed          Journal:  Bull Cancer        ISSN： 0007-4551            Impact factor:   1.276


× No keyword cloud information.
  15 in total

1.  Elevation of carcinoembryonic antigen and CA-125 in a patient with multivisceral tuberculosis.

Authors:  M Mansour; E R Linden; S Colby; G Posner; F Marsh
Journal:  J Natl Med Assoc       Date:  1997-02       Impact factor: 1.798

2.  Increased CA 125 in tuberculous peritonitis.

Authors:  J Collazos
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

3.  Serum CA 125 levels in patients with non-malignant liver diseases without ascites.

Authors:  J Collazos; J Genolla; M T Allende; A Ruibal
Journal:  Clin Investig       Date:  1993-03

4.  Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients.

Authors:  M M Uttenreuther-Fischer; H Feistel; F Wolf; W Jäger
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

5.  Purification and immunochemical characterization of ascitic fluid glycoproteins containing certain tumor-associated and blood group antigen markers.

Authors:  M Venegas; L Liu; L Lovell; L E Davis; B Anderson; T Wilbanks; M Hass; G Manderino; H Rittenhouse
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

Review 6.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

7.  Pelvic mass associated with raised CA 125 for benign condition: a case report.

Authors:  Viren Asher; Robert Hammond; Tim J Duncan
Journal:  World J Surg Oncol       Date:  2010-04-16       Impact factor: 2.754

8.  Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer.

Authors:  Aaron M Carlson; Matthew J Maurer; Krista M Goergen; Kimberly R Kalli; Courtney L Erskine; Marshall D Behrens; Keith L Knutson; Matthew S Block
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-22       Impact factor: 4.254

9.  [Monoclonal antibodies in the diagnosis and follow-up of ovarian cancer. CA 125 as a tumor marker. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].

Authors:  H Kaesemann; H Caffier; F J Hoffmann; G Crombach; H Würz; R Kreienberg; V Möbus; P Schmidt-Rhode; G Sturm
Journal:  Klin Wochenschr       Date:  1986-09-01

10.  CA 125 in the serum and tissue of patients with gynecological disease.

Authors:  L C Fuith; G Daxenbichler; O Dapunt
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.